CART-38 in Adult AML and MM Patients
NCT05442580
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This study is being done to see if a new treatment called CART-38 cells is safe and can be made in a lab. It will be tested on patients with two types of cancer called Acute Myeloid Leukemia and Multiple Myeloma. The treatment involves changing the patient's cells to help fight the cancer.
This study is being done to see if a new treatment called CART-38 cells is safe and can be made in a lab. It will be tested on patients with two types of cancer called Acute Myeloid Leukemia and Multiple Myeloma. The treatment involves changing the patient's cells to help fight the cancer.
Third Opinion AI Generated Synopsis
Trial Summary
This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patients with Acute Myeloid Leukemia and Multiple Myeloma. This CAR T cell product will be referred to as "CART-38 cells".
This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patients with Acute Myeloid Leukemia and Multiple Myeloma. This CAR T cell product will be referred to as "CART-38 cells".
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
